China Biologic Products Holdings Inc (CBPO) Receives Consensus Recommendation of “Hold” from Brokerages

Shares of China Biologic Products Holdings Inc (NASDAQ:CBPO) have earned an average rating of “Hold” from the seven ratings firms that are presently covering the stock, MarketBeat Ratings reports. Two analysts have rated the stock with a sell rating, three have given a hold rating and one has issued a buy rating on the company. The average twelve-month target price among analysts that have issued ratings on the stock in the last year is $105.00.

CBPO has been the subject of several recent research reports. Credit Suisse Group downgraded shares of China Biologic Products from an “outperform” rating to a “neutral” rating in a research note on Monday, August 6th. Zacks Investment Research downgraded shares of China Biologic Products from a “hold” rating to a “strong sell” rating in a research note on Thursday, August 9th. BidaskClub downgraded shares of China Biologic Products from a “hold” rating to a “sell” rating in a research note on Saturday, August 18th. Finally, ValuEngine downgraded shares of China Biologic Products from a “hold” rating to a “sell” rating in a research note on Friday, August 24th.

China Biologic Products stock traded down $0.75 during mid-day trading on Tuesday, hitting $80.00. The company’s stock had a trading volume of 173,489 shares, compared to its average volume of 232,272. The company has a market capitalization of $2.70 billion, a PE ratio of 16.16, a P/E/G ratio of 1.69 and a beta of 1.25. China Biologic Products has a 12 month low of $71.85 and a 12 month high of $107.44.

China Biologic Products (NASDAQ:CBPO) last posted its quarterly earnings results on Friday, August 3rd. The biopharmaceutical company reported $1.17 earnings per share for the quarter, missing the consensus estimate of $1.26 by ($0.09). The business had revenue of $120.40 million during the quarter, compared to the consensus estimate of $116.21 million. China Biologic Products had a return on equity of 14.00% and a net margin of 15.89%. The business’s revenue for the quarter was up 34.8% on a year-over-year basis. During the same period in the prior year, the firm earned $1.35 earnings per share. analysts predict that China Biologic Products will post 3.71 earnings per share for the current year.

Several large investors have recently modified their holdings of the company. FMR LLC raised its stake in shares of China Biologic Products by 0.3% during the second quarter. FMR LLC now owns 234,100 shares of the biopharmaceutical company’s stock valued at $23,253,000 after acquiring an additional 700 shares during the last quarter. GSA Capital Partners LLP raised its stake in shares of China Biologic Products by 2.5% during the first quarter. GSA Capital Partners LLP now owns 28,910 shares of the biopharmaceutical company’s stock valued at $2,342,000 after acquiring an additional 710 shares during the last quarter. Azimuth Capital Management LLC raised its stake in shares of China Biologic Products by 13.8% during the first quarter. Azimuth Capital Management LLC now owns 20,375 shares of the biopharmaceutical company’s stock valued at $1,650,000 after acquiring an additional 2,470 shares during the last quarter. Myriad Asset Management Ltd. bought a new position in shares of China Biologic Products during the second quarter valued at about $348,000. Finally, Parametrica Management Ltd bought a new position in shares of China Biologic Products during the second quarter valued at about $386,000. 44.22% of the stock is owned by hedge funds and other institutional investors.

China Biologic Products Company Profile

China Biologic Products Holdings, Inc engages in the research, development, manufacture, and sale of human plasma-based biopharmaceutical products to hospitals and inoculation centers in the People's Republic of China. It offers human albumin for treating shock caused by blood loss trauma or burn; raised intracranial pressure caused by hydrocephalus or trauma; oedema or ascites caused by hepatocirrhosis and nephropathy; and neonatal hyperbilirubinemia, as well as for the prevention and treatment of low-density-lipoproteinemia.

Featured Article: Trading Penny Stocks

Receive News & Ratings for China Biologic Products Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for China Biologic Products and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply